文献速递肝病

超重或肥胖成人中代谢功能障碍相关脂肪性肝病的全球患病率

Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-02-20

本研究通过系统综述和荟萃分析,纳入116项研究共2,667,052名普通人群参与者,估算超重或肥胖成人中MAFLD的全球患病率为50.7%(95%CI 46.9-54.4)。男性患病率59.0%高于女性47.5%,超声诊断的患病率为51.3%。

要点

  • 超重或肥胖成人中MAFLD全球患病率高达50.7%。
  • 男性患病率(59.0%)显著高于女性(47.5%)。
  • 合并2型糖尿病和代谢综合征的患病率分别为19.7%和57.5%。

核心结论

  • MAFLD在超重或肥胖成人中患病率极高,需引起初级保健医生、专科医生、政策制定者和公众的重视。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、Embase、Web of Science、Cochrane和Google Scholar至2020年11月,纳入116项研究共2,667,052名普通人群参与者。

主要发现

  • 超重或肥胖成人中MAFLD全球患病率为50.7%(95%CI 46.9-54.4)。
  • 超声诊断的患病率为51.3%(95%CI 49.1-53.4)。
  • 男性患病率为59.0%(95%CI 52.0-65.6),女性为47.5%(95%CI 40.7-54.5)。
  • 合并2型糖尿病的患病率为19.7%(95%CI 12.8-29.0),合并代谢综合征的患病率为57.5%(95%CI 49.9-64.8)。

临床怎么用

  • 在超重或肥胖成人中应重视MAFLD的筛查与评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new terminology updated from non-alcoholic fatty liver disease (NAFLD). In this study, we aim to estimate the global prevalence of MAFLD specifically in overweight and obese adults from the general population by performing a systematic review and meta-analysis through mining the existing epidemiological data on fatty liver disease. METHODS: We searched Medline, Embase, Web of Science, Cochrane and google scholar database from inception to November, 2020. DerSimonian-Laird random-effects model with Logit transformation was performed for data analysis. Sensitivity analysis and meta-regression were used to explore predictors of MAFLD prevalence in pooled statistics with high heterogeneity. RESULTS: We identified 116 relevant studies comprised of 2,667,052 participants in general population with an estimated global MAFLD prevalence as 50.7% (95% CI 46.9-54.4) among overweight/obese adults regardless of diagnostic techniques. Ultrasound was the most commonly used diagnostic technique generating prevalence rate of 51.3% (95% CI, 49.1-53.4). Male (59.0%; 95% CI, 52.0-65.6) had a significantly higher MAFLD prevalence than female (47.5%; 95% CI, 40.7-54.5). Interestingly, MAFLD prevalence rates are comparable based on classical NAFLD and non-NAFLD studies in general population. The pooled estimate prevalence of comorbidities such as type 2 diabetes and metabolic syndrome was 19.7% (95% CI, 12.8-29.0) and 57.5% (95% CI, 49.9-64.8), respectively. CONCLUSIONS: MAFLD has an astonishingly high prevalence rate in overweight and obese adults. This calls for attention and dedicated action from primary care physicians, specialists, health policy makers and the general public alike.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Liu J, Ayada I, Zhang X, et al. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults. Clin Gastroenterol Hepatol. 2021. PMID: 33618024. doi:10.1016/j.cgh.2021.02.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。